Weekly Recap: sefaxersen UPCR cut wk37 and enicepatide cuts HbA1c, weight
Roche Holding Ltd (SIX:RO) posted a string of clinical and regulatory wins: Phase III IMAgINATION showed sefaxersen cut UPCR, Phase II enicepatide met diabetes and weight endpoints, the EC approved Susvimo with Contivue for nAMD, and the board nominated Dr. Christophe Weber for 2027 AGM.Previous We…